
Opinion|Videos|December 18, 2024
Overview of Frontline Luspatercept in LR-MDS
Author(s)Guillermo Garcia-Manero, MD, David Swoboda, MD
Panelists discuss how frontline luspatercept is emerging as an effective treatment for anemia in lower-risk myelodysplastic syndrome (LR-MDS), demonstrating significant improvements in hemoglobin levels and transfusion independence, as supported by clinical trial data.
Advertisement
Episodes in this series

Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Dr Cloughesy on Extended Follow-Up Data for Vorasidenib in IDH1/2 Mutant Glioma
2
Bispecific ADC Iza-Bren Extends Survival in Advanced TNBC
3
ASCO 2026 GU Cancer Highlights: Beyond the LBAs
4
FDA Grants Priority Review to Giredestrant for ER+/HER2- Breast Cancer
5
































